Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....

BIOGEN PHARMACHEM INDUSTRIES LIMITED CIN NO: L51100GJ1995PLC026702 (Formerly Known as SUN TECHNO OVERSEAS LIMITED) Date.:05.08.2026 Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Ref: Scrip Code: 531752 Scrip ID: BIOGEN Dear Sir / Madam, Subject: Outcome of Board Meeting held on 5th August 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 5th August,2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2026. The board meeting commented at 03:15 PM and concluded at 03:35 PM Please take the above intimation in your records. Thanking You Yours Faithfully, FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED KELASH BUNKAR WHOLE TIME DIRECTOR DIN: 10911360 Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001 E mail biogenpharmachem@gmail.com Biogen Pharmachem Industries Ltd CIN:- L51100GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com (Rs. In lacs) Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2026 Quarter Ended Year Ended Sl no. Particulars 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 (Refer Notes Below) (Unaudited) (Audited) (Unaudited) (Audited) INCOME (a) Gross Revenue from sale of products - - - - (b) Other Operating Revenue 44.34 57.82 154.28 255.80 1 Revenue from Operations 44.34 57.82 154.28 255.80 2 Other Income - - - - 3 Total Income 44.34 57.82 154.28 255.80 EXPENSES (a) Cost of materials consumed - - - - (b) Purchases of Stock-in-Trade - (c) Changes in inventories of finished goods, work-in-progress, - - - - and stock-in-trade (d) Employee benefit expense 2.28 10.31 6.33 2 8.28 (e) Finance Costs - - - - (f) Depreciation and amortization expense - - - - (g) Other expenses 19.92 83.39 13.47 1 31.85 4 Total Expenses 22.20 93.70 19.80 1 60.13 5 Profit / (Loss) from operations before exceptional items 22.14 ( 35.88) 134.48 9 5.67 Tax (1-2) 6 Exceptional Items - - - - 7 Profit / (Loss) before Tax (5 ± 6) 22.14 ( 35.88) 134.48 9 5.67 8 Tax Expense - - - 9.73 9 Net Profit / (Loss) after Tax (7 - 8) 22.14 ( 35.88) 134.48 8 5.95 10 Other Comprehensive Income (net of tax ) - - - - (i) Items that will not be reclassified to profit or loss - - - - A (ii) Income tax relating to items that will not be reclassified to - - - - profit or loss (i) Items that will be reclassified to profit or loss - - - - B (ii) Income tax relating to items that will be reclassified to - - - - profit or loss Total Comprehensive Income for the period (9 ± 10) 22.14 ( 35.88) 134.48 8 5.95 12 Paid-up equity share capital (Face Value of Rs.1/- each) 10,530.37 9,026.03 9,026.03 9 ,026.03 13 Other Equity - - - 8 82.68 14 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic 0.00 ( 0.00) 0.01 0 .01 (b) Diluted 0.00 ( 0.00) 0.01 0 .01 Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 05, 2026. The Statutory Auditors have carried out a limited review of the above financial result. 2 Company has only one segment and hence no separate segment result has been given. 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Biogen Pharmachem Industries Ltd Kelash Bunkar Place : Rajkot Whoetime-Director Date : 05th August, 2026 DIN: 10911360 Goenka Mehta And Associates CHARTERED ACCOUNTANTS Limited Review Report on unaudited standalone financial results of Biogen Pharmachem Industries Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Biogen Pharmachem Industries Limited 1. We have reviewed the accompanying Statement of unaudited stflndalone financial results of Biogen Pharmachem Industries Limited for the quarter ended 30 June 2026 ("the Statement")' being submitted by the Company pursuant to the requirements uf Regulation33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation i..Jf the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of t:le Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of IndiS3,. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and.. applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as abOVe, nothing has come to our attention that causes us to believe that the accompanying Statement, not prepared in accordance with the' recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For, Mis. Goenka Mehta & Associates Chartered Accountants FRN No.: 129445W PLACE: RAJKOT DATE: 05/08/2026 UDIN: 26130401JXXFMD8520 Offices at Ahmedabad and Rajkot